OSF Illinois Neurological Institute

Clinical Trials & Research

The OSF HealthCare Illinois Neurological Institute (OSF INI) Multiple Sclerosis Center is currently conducting or participating in the following clinical trials and research:

  • Demographic and clinical characteristics of individuals with MS being treated by the INI MS Center
  • Ambient air quality: correlation between relapses in multiple sclerosis and ambient air quality in Central Illinois
  • Vitamin D: Correlation between relapses in multiple sclerosis (MS) and vitamin D intake
  • In development: MS outcome studies, 
  • BRAVO (Phase III)-  A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis
  • ESTEEM (Phase IV)  - A multicenter, global, observational study to collect information on safety and to document the drug utilization of Tecfidera™ (dimethyl dumarate) when used in routine medical practice in the treatment of Multiple Sclerosis
  • PASSAGE (Phase IV): Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy